This is a third-party event.
Company Presenting: Oxford Biodynamics plc
Time: 2pm, on Tuesday 24th January
Event: Jon Burrows, CEO presents the FY results which are released on 24 January and updates on current performance.
Register: click here
Company Description: Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
Presenter: Jon Burrows, CEO
Bio: Jon’s 25 year career in science and medicine has been built on increasing levels of responsibility in scientific leadership, business development, commercialization and executive management at both early-stage biotech and large multinational biomedical entities including Pharmacia/SUGEN, Rigel, Chiron, Novartis, Ventana, Roche, Expression Pathology and OncoPlex Diagnostics. In his early career, Jon was in oncology drug development, where he became skilled at driving molecular diagnostics tied to drug development to advance precision medicine and advocate for personalized healthcare. Most recently Jon was a Managing Partner at Oncology Partners (NYC), a consulting and clinical advisory firm he co-founded, focused on providing strategic counsel to development-stage pharma, biotech, medical devices and diagnostic companies.
Please note that this webinar has been organised by Yellowstone Advisory